Sector • Healthcare Industry • Medical Equipment & Supplies |
Industry • Medical Equipment & Supplies |
Sector • Healthcare |
Very steep Deterioration at TTOO amid the third quarter of 2022 earnings season
TTOO recorded third quarter of 2022 operating deficit of $-15.8 million
Published Mar 22 2023
CSIMarket Team / CSIMarket.com
from the preceding reporting period from $-0.10 per share, Revenue Tumbled from the by -37.794 % from $5.91 million.
For the third quarter of 2022 T2 Biosystems Inc realized net loss of $-17.375 million, higher than $-13.962 million a year ago.
T2 Biosystems Inc is expected to report next financial earnings on May 11, 2023.
Other TTOO's news
T2 Biosystems Unveils T2Lyme Launch Plans and Projections for Future Success
T2 Biosystems Strengthens Disease Diagnostics with T2Lyme Launch and Expanded Bacteria Panel
Advancements in T2Resistance Panel Enable Faster Targeted Therapy for Drug-Resistant Infections
T2 Biosystems: Building a Stronger Future Through Strategic Financial Moves
T2 Biosystems Joins Forces with NIH in Groundbreaking Study to Revolutionize Pneumonia Diagnosis
T2 Biosystems Struggles Amidst Stock Decline and Financial Losses
Very steep Deterioration at TTOO amid the third quarter of 2022 earnings season
Other TTOO's news
T2 Biosystems Unveils T2Lyme Launch Plans and Projections for Future Success
T2 Biosystems Strengthens Disease Diagnostics with T2Lyme Launch and Expanded Bacteria Panel
Advancements in T2Resistance Panel Enable Faster Targeted Therapy for Drug-Resistant Infections
T2 Biosystems: Building a Stronger Future Through Strategic Financial Moves
T2 Biosystems Joins Forces with NIH in Groundbreaking Study to Revolutionize Pneumonia Diagnosis
T2 Biosystems Struggles Amidst Stock Decline and Financial Losses
Very steep Deterioration at TTOO amid the third quarter of 2022 earnings season